6281
document
Dose response effect of cyclical medroxyprogesterone on blood pressure in postmenopausal women . OBJECTIVE This study was designed to compare with placebo the dose-response effect of cyclical doses of the C21 progestogen , medroxyprogesterone acetate ( MPA ) on blood pressure ( BP ) when administered to normotensive postmenopausal women receiving a fixed mid-range daily dose of conjugated equine oestrogen ( CEE ) . MATERIALS AND METHODS Twenty normotensive postmenopausal women ( median age 53 years ) participated in the study which used a double-blind crossover design . There were four randomised treatment phases , each of 4 weeks duration . The four blinded treatments were MPA 2.5 mg , MPA 5 mg , MPA 10 mg and matching placebo , taken for the last 14 days of each 28 day treatment cycle . CEE 0.625 mg was also administered once daily as open labelled tablets to all subjects throughout the study . Clinic BP was measured weekly with the mean values of weeks 3 and 4 of each phase used for analysis . Ambulatory BP was performed in the final week of each phase . RESULTS Compared with the placebo phase , end of phase clinic BP was unchanged by any of the progestogen treatments . There was a dose-dependent decrease in ambulatory daytime diastolic and mean arterial BP with the progestogen treatments compared with placebo ( P < 0.05 ) . CONCLUSION In a regimen of postmenopausal hormone replacement therapy with a fixed mid-range daily dose of CEE combined with a cyclical regimen of a C21 progestogen spanning the current clinical dose range , the progestogen has either no effect or a small dose-dependent reduction in clinic and ambulatory BPs over one treatment cycle .
6282
Intervention_Pharmacological
cyclical medroxyprogesterone
6283
Intervention_Control
placebo
6284
Intervention_Pharmacological
C21 progestogen
6285
Intervention_Pharmacological
medroxyprogesterone acetate
6286
Intervention_Pharmacological
conjugated equine oestrogen ( CEE
6287
Intervention_Physical
)
6288
Intervention_Pharmacological
MPA 2.5 mg , MPA 5 mg , MPA 10 mg
6289
Intervention_Control
placebo
6290
Intervention_Pharmacological
CEE
6291
Intervention_Pharmacological
progestogen
6292
Outcome_Physical
blood pressure
6293
Outcome_Physical
Clinic BP
6294
Outcome_Physical
Ambulatory BP
6295
Outcome_Physical
clinic BP
6296
Outcome_Physical
decrease in ambulatory daytime diastolic and mean arterial BP
6297
Outcome_Physical
clinic and ambulatory BPs
6298
Participant_Condition
postmenopausal
6299
Participant_Sex
women
6300
Participant_Condition
.
6301
Participant_Condition
normotensive postmenopausal
6302
Participant_Sex
women
6303
Participant_Condition
receiving a fixed mid-range daily dose of conjugated equine oestrogen ( CEE )
6304
Participant_Condition
normotensive postmenopausal
6305
Participant_Age
median age 53 years